SRF Limited, a chemical based multi-business entity engaged in the manufacturing of industrial and specialty intermediates  announced its consolidated financial results for the third quarter and nine months ended December 31, 2025.

The consolidated revenue of the company increased 6 per cent from Rs. 3,491 crore to Rs. 3,713 crore in Q3FY26 when compared with Corresponding Period Last Year (CPLY). The company’s Earnings before Interest and Tax (EBIT) increased 23 per cent from Rs. 529 crore to Rs. 653 crore in Q3FY26 when compared with CPLY. The company’s Profit after Tax (PAT) increased 60 per cent from Rs. 271 crore to Rs. 433 crore in Q3 FY26 when compared with CPLY.

Commenting on the results, Chairman and Managing Director, Ashish Bharat Ram said, “On an overall basis, this has been a good quarter for the company. Despite a very volatile environment, we have been able to generate a reasonable growth in revenue along with a much-improved bottom line. We remain cautiously optimistic about the future.”

Consolidated Q3FY26 Segment Results

The Chemicals Business reported an increase of 22 per cent in its segment revenue from Rs. 1,496 crore to Rs. 1,825 crore during Q3FY26 over CPLY. The operating profit of the Chemicals Business increased 36 per cent from Rs. 364 crore to Rs. 496 crore in Q3FY26 over CPLY. During the quarter, the Fluorochemicals Business delivered a record quarter driven by strong refrigerant gas performance, supported by firm global HFC prices, recovering domestic demand, and healthy overseas growth. The Specialty Chemicals Business saw muted quarterly performance due to aggressive Chinese pricing and deferred offtake by key customers, though the Business continues to strengthen its long‑term foundation with improved product mix, operational efficiencies, robust R&D progress, and a strong pipeline of agrochemical and pharma molecules.

The Performance Films & Foil Business reported a decline of 3 per cent in its segment revenue from Rs. 1,385 crore to Rs. 1,342 crore during Q3FY26 when compared with CPLY. The operating profit of the Performance Films & Foil Business increased 5 per cent from Rs. 90 crore to Rs. 95 crore in Q3FY26 over CPLY. During the quarter, the Performance Films & Foil Business saw temporary GST 2.0–related disruption, however domestic demand for BOPET began recovering, with early signs of price improvement from China. Focus on exports of Aluminium Foil and continued push on Value‑Added Products position the Business for stronger performance ahead.

The Technical Textiles Business reported a decline of 11 per cent in its segment revenue from Rs. 510 crore to Rs. 454 crore during Q3FY26 over CPLY. The operating profit of the Technical Textiles Business decreased 24 per cent from Rs. 59 crore to Rs. 45 crore in Q3FY26 over CPLY. This quarter, the Technical Textiles Business faced a challenging environment marked by continued pressure on Belting Fabrics due to aggressive Chinese pricing and lower conveyor belt exports to the United States.

The Other Businesses reported a decline of 9 per cent in its segment revenue from Rs. 101 crore to Rs. 92 crore in Q3FY26 when compared with CPLY. The operating profit of the Other Businesses increased 8 per cent from Rs. 16 crore to Rs. 17 crore in Q3FY26 over CPLY. During the quarter, Coated Fabrics saw lower volumes due to cheaper Chinese imports and Laminated Fabrics continued to face strong pricing pressure after the Minimum Import Price withdrawal.

9M FY26 Financials

In the first nine months of FY26, SRF’s revenue increased 8 per cent from Rs. 10,380 crore to Rs. 11,171 crore over CPLY. The company’s PAT increased 73 per cent from Rs. 725 crore to Rs. 1,253 crore over CPLY.

Following the Government of India’s notification implementing the Labour Codes effective November 21, 2025, introducing a uniform definition of wages, the Company has reassessed its employee benefit obligations.

Consequently, an additional gratuity and leave liability of Rs. 73 crore has been recognised in the consolidated financial results for the quarter.

Capex

The Board has approved the establishment of a new pharma intermediates plant facility at Dahej, with an estimated investment of Rs. 180 crore.

Innovation and Intellectual Property

As of December 31, 2025, the company has applied for a total of five hundred and six patents. Till date, the company has been granted one hundred and fifty-three patents globally.

Awards and Recognition

Chairman Emeritus, Arun Bharat Ram was honoured with the ‘Lifetime Achievement in Multigenerational Family Enterprise & Global Industrial Advancement Award’ by Hurun India at the ‘India’s Most Respected Family Business Excellence Awards 2025.